LB Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-9.2%projected annual EPS growth
Analyst Coverage
8analysts covering
FY EPS (est.)
-$5.56next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results & Corporate Update | 15 Nov 2026 |
| FY 2026 Annual Report (Form 10-K) | 31 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Cash Runway (Years) Quarterly3.0Target: Fund operations into Q2 2029
Phase 3 NOVA-2 Trial Enrollment QuarterlyTarget: Approximately 460 patients across 25 U.S. sites
Phase 2 ILLUMINATE-1 Trial Enrollment QuarterlyTarget: Approximately 320 patients across 30 U.S. sites
Watch Items
- Phase 3 NOVA-2 Topline Data in SchizophreniaTrigger: Data release in H1 2027Action: Evaluate primary efficacy endpoint (PANSS score change at 6 weeks) and safety profile to prepare for pre-NDA meeting with FDA.
- Phase 2 ILLUMINATE-1 Topline Data in Bipolar DepressionTrigger: Data release in 1Q 2028Action: Assess MADRS-10 score change at week 6 to determine registrational path for bipolar depression.
- Phase 2 Adjunctive MDD Trial InitiationTrigger: Trial initiation in early 2027Action: Monitor site activation and patient screening for the planned 380-patient study.
Research as of 19 Jun 2026